IRIS Expands AI Partnerships with Thirona Retina BV

Intelligent Retinal Imaging Systems (IRIS), a leader in retinal screening technology, today announced a partnership with Thirona Retina BV, a leading artificial intelligence company for retinal image analysis and diagnostics. Under the agreement, IRIS will license the Class IIa European MDR CE certified RetCAD™ software from Thirona Retina BV for use in its current and future customers in international markets.

This partnership allows IRIS customers to use RetCAD™   for the detection of diabetic retinopathy (DR), glaucoma, and age-related macular degeneration (AMD) while integrated with the IRIS Solution.  The high sensitivity and specificity of the RetCAD™ solution make it best in its class and will benefit more patients by early detection of the diseases.

“We are pleased to announce an additional partnership with Thirona Retina BV,” said Steve Martin, CEO of IRIS. “Our current and future international customers will now be able to use the CE Marked RetCAD™ within their retinal screening programs. Their unique single-image-capture-per-eye requires less work and detects three eye care pathologies with one retinal image. Furthermore, we look forward to US-based regulatory approvals in the future.”

“Partnering with IRIS is another major step forward in making innovative technology like RetCAD™ widely available to benefit patients all over the world,” said Mark van Grinsven, Managing Director Thirona Retina. “Integration of our software into the IRIS platform will help clinicians to process more patient cases faster, with even more accuracy.” 

About IRIS

Intelligent Retinal Imaging Systems’(IRIS) mission is to end preventable blindness. Their end-to-end comprehensive diagnostic solution enables the provision of retinal imaging services in a variety of settings to persons at risk for developing sight-threatening diseases. The IRIS software is an FDA Class II cleared cloud-based platform which offers clients the unique ability to customize their program from hardware to workflow, ultimately improving quality, increasing access, and reducing costs, but most importantly helping to end vision loss due to diabetic retinopathy. For more information, visit www.retinalscreenings.com.

About Thirona Retina

Thirona Retina BV is a spin-out company of a Dutch-based Thirona BV, specializing in the field of AI-assisted medical image analysis for eye disease screening, with RetCAD™ as its flagship product platform. 

RetCAD™ is a CE (0344) certified software product using artificial intelligence that analyses color fundus images for the presence of Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma. It assists eye care providers in early diagnosis and grading of the vision threatening diseases. RetCAD™ uses state-of-the-art deep learning and computer vision technology, utilizing large amounts of human-specialist graded images, to provide quantified clinical outcome measures. 

Having every patient fundus examination instantly analyzed with a clinically validated software system, initial screening procedures can be done more efficiently and at least as accurately as when conducted by human experts. Simplified visualization of the examination analysis with heat maps supports clinicians in validating the AI results and helps improve patient engagement in the prevention of severe eyesight problems and blindness.

RetCAD™ is available to clinical and optical markets through integration partnerships with all major fundus camera vendors and eye care solutions providers such as iCare, Optomed, Topcon, Canon, Tomey, and Nidek. The Class IIa European MDR CE certification proves the highest quality assurance and the long-term commitment of Thirona Retina as a trusted technology partner for eye care.